NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE & MUNICH--(BUSINESS WIRE)--NanoString Responds to Decision of the Regional Court of Munich.

NanoString Responds to Decision of the Regional Court of Munich

10X Genomics

10x Genomics is seeking additional injunctions to protect its intellectual property PLEASANTON, Calif. , May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and NanoString Technologies Germany GmbH.

10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products

NanoString Technologies (NSTG) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.86 per share a year ago.

NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports operating results for first quarter of 2023.

NanoString Technologies Releases Operating Results for First Quarter of 2023

SEATTLE--(BUSINESS WIRE)--NanoString to report Q1 2023 operating results on May 3, 2023.

NanoString to Release First Quarter 2023 Operating Results and Host Conference Call on Wednesday, May 3, 2023

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to participate in a panel discussion, “AI-Driven Disruptions To Genomics & Computational Drug Discovery”, from the 43rd Annual Cowen Health Care Conference. The conference will be held March 6-8, 2023.

NanoString to Webcast Panel on AI-Based Genomics and Drug Discovery from the 43rd Annual Cowen Health Care Conference

NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports Q4 and FY22 operating results.

NanoString Technologies Releases Fourth Quarter and Full Year 2022 Operating Results and Provides 2023 Financial Outlook

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 43rd Annual Cowen Health Care Conference. The conference will be held March 6-8, 2023. Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, March 7, 2023, at 1:30pm ET.

NanoString to Webcast Presentation from the 43rd Annual Cowen Health Care Conference

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report fourth quarter and fiscal year 2022 operating results after the close of the market on Tuesday, February 28, 2023. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.

NanoString to Release Fourth Quarter and Fiscal Year 2022 Operating Results and Host Conference Call on Tuesday, February 28, 2023

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced an update to the technology roadmap for the CosMx™ Spatial Molecular Imager (SMI) that will be presented at the 2023 Advances in Genome Biology and Technology General Meeting in Hollywood, FL. The Company is hosting the Gold Sponsor workshop on Tuesday, February 7th from 12:00-1:30pm EST. This event will also be live-streamed and interested parties can use this link to register.

NanoString Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology (AGBT)

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy (SAHA) initiative, in collaboration with Weill Cornell Medicine, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults.

Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a public release of new data generated by the CosMx™ Spatial Molecular Imager (SMI). This data was generated from formalin-fixed paraffin-embedded (FFPE) human liver samples and showcases the best-in-class data quality of the CosMx SMI. The dataset highlights CosMx SMI's high sensitivity, with the capability to detect and quantify an average of 1,150 transcripts per cell and to maximize biological insights by detecting 676 unique genes. The dataset also represents CosMx SMI's high specificity, with more than 99% of identified counts on targeted genes.

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the fourth quarter and fiscal year ended December 31, 2022.

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company's management is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.

NanoString to Present at the 41st Annual J.P. Morgan Healthcare Conference

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company's CosMx™ Spatial Molecular Imager (SI) has been recognized by The Scientist magazine as one of the Top 10 Innovations of the 2022 (https://www.the-scientist.com/ts-digest/view/the-scientist-top-10-innovations-2022-12-2). This recognition identifies CosMx SMI as a product poised to revolutionize research and advance scientific knowledge with the potential to foster rapid advances and address specific problems in their respective fields.

NanoString's CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022

SEATTLE--( BUSINESS WIRE )--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the first commercial shipment of the CosMx™ Spatial Molecular Imager (SMI) and the AtoMx™ Spatial Informatics Platform (SIP).

NanoString Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences.

NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences

Abcam

SEATTLE & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString's high-plex spatial multiomic so

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates

NanoString Technologies, Inc. (NASDAQ:NSTG ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Doug Farrell - Vice President, Investor Relations Brad Gray - President and Chief Executive Officer Tom Bailey - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Dan Brennan - Cowen Dan Arias - Stifel Catherine Schulte - Baird Edmund Debler - Morgan Stanley Operator Good afternoon. Thank you for attending today's NanoString Third Quarter 2022 Operating Results Conference Call.

NanoString Technologies, Inc. (NSTG) Q3 2022 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2022.

NanoString Technologies Releases Operating Results for Third Quarter of 2022

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Visiopharm, a world leader in AI-driven digital pathology software, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.

NanoString and Visiopharm Announce Collaboration to Co-develop Integrated Workflows for GeoMx and AtoMx Spatial Biology Solutions

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString announced the publication of its first paper describing the CosMx™ Spatial Molecular Imager's (SMI) in Nature Biotechnology.

Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report third quarter 2022 operating results after the close of the market on Monday, November 7, 2022.

News for NanoString Technologies Stock (NSTG)